From our results, oXiris-CHFA treatment initiated in the early stage of sepsis (AKI stage 1) may reduce the levels of proinflammatory factors such as IL-6 more significantly than in the later stage (AKI stage 2–3). This evidence concerns the gene IL6 and acute kidney injury.